The Warning Just Disappeared. Here's What Actually Changed.

In February 2025, the FDA made a change to testosterone product labeling that most men never heard about, and most still haven't. It removed the black box warning for cardiovascular risk that had been required on every testosterone product since 2014 and 2015.

If you've noticed testosterone therapy feeling more accessible over the past year or so, more telehealth platforms, more casual conversation about it, less hesitation from prescribers, this label change is part of the reason. But what actually changed is narrower, and more important, than most of the coverage suggests.

WHAT A BLACK BOX WARNING ACTUALLY IS

A black box warning is the FDA's strongest labeling requirement. It sits in a bordered box at the top of a drug's prescribing information, and it exists for one reason: to force a pause. Prescribers are required to read it before writing a prescription. Pharmacists are required to be aware of it when they fill one. It's a mechanism built to slow down a decision that might otherwise move too fast.

Starting in 2014, following a series of observational studies that raised concern about cardiovascular events in men using testosterone products, the FDA required every manufacturer, of gels, injections, patches, and pellets alike, to carry a boxed warning stating a possible increased risk of heart attack and stroke.

That warning did what it was designed to do. It made testosterone therapy feel dangerous by default, for over a decade. Some physicians declined to prescribe it at all. Some men who might have been reasonable candidates for treatment never got a full conversation about it because the label made the entire category feel like it should be avoided.

THE TRIAL THAT CHANGED THE PICTURE

The original warning was built on data that raised a signal without settling the question. Observational studies can suggest a pattern, but they can't prove it, because the men taking testosterone in those studies weren't randomly assigned, and the studies couldn't fully account for the other health differences between men who were prescribed testosterone and men who weren't.

TRAVERSE was designed to settle it properly. It was a large, randomized, placebo-controlled trial, the kind of study built specifically to answer a cardiovascular safety question. It enrolled more than 5,200 men between the ages of 45 and 80, all of whom had existing cardiovascular risk factors or diagnosed cardiovascular disease, which made them a higher-risk population than the general TRT candidate. Half received testosterone, half received placebo, and both groups were followed for major adverse cardiac events, meaning heart attack, stroke, and cardiovascular death.

The result: testosterone was not associated with an increased rate of those events. The two groups landed within a fraction of a percentage point of each other. That is a meaningful finding, and it's the primary reason the FDA acted.

In February 2025, the agency required manufacturers to remove the cardiovascular language from the boxed warning across the entire testosterone product class. In its place, it required a new, more specific warning: an increase in blood pressure, which the same data consistently showed across testosterone products regardless of formulation.

WHAT THE TRIAL DIDN'T CLEAR

This is the part that gets flattened in most of the coverage. TRAVERSE cleared testosterone on the specific outcome the original warning was about, major cardiac events. It did not find that testosterone therapy carries no risk at all. The same trial identified higher rates of three other outcomes in the group taking testosterone: atrial fibrillation, pulmonary embolism, and acute kidney injury.

None of those findings made it into a boxed warning, because a boxed warning is reserved for the most serious, most well-established risks, and the agency's process for adding new warning language works differently than removing old language. But they are documented, real findings from the same trial that justified taking the old warning off, and any responsible conversation about testosterone therapy in 2026 has to include them.

A label change also operates at the population level, not the individual level. TRAVERSE tells you what was true, on average, for a specific group of men: mostly older, mostly with pre-existing cardiovascular risk factors. It doesn't tell you what's true for a 38-year-old with no cardiovascular history, or a 55-year-old with untreated hypertension. Those men need their own picture, built from their own bloodwork and their own risk profile, not a label that was written for a trial population they may not resemble.

WHAT ACTUALLY CHANGES, AND WHAT DOESN'T

Here is the honest read on what this label change means in practice. It lowers a barrier. Prescribers who were cautious because of the boxed warning have less reason to be. Telehealth platforms that built hesitation into their intake process have less reason to. Testosterone therapy is going to keep getting easier, faster, and more common to access, and that shift is already underway.

But access was never the difficult part of doing this well. The difficult part was always what happens after the first prescription is written: whether someone is tracking blood pressure over time, watching hematocrit for the kind of elevation that raises clotting risk, monitoring estradiol so a man doesn't end up dealing with mood swings or a paradoxical drop in libido, and checking PSA at the intervals that responsible prescribing requires.

The old warning label did some of that vigilance work for the entire industry, whether or not any individual prescriber intended it to. It forced a pause that made careless prescribing harder to get away with. Now that the label is simpler, that pause doesn't happen automatically anymore. The responsibility for it doesn't disappear along with the warning. It just moves entirely onto whoever is actually managing the care.

That is the standard this practice holds itself to, independent of what any label requires. Testosterone therapy, done well, isn't a prescription. It's a relationship with your own bloodwork over time, adjusted as the numbers move, not left alone because a form said it was safe

If you're considering testosterone therapy, or you're already on it without regular lab monitoring, a consultation is the place to find out exactly where you stand. It starts with a $100 deposit, applied toward whatever services make sense once we have your full picture.

Springhouse Men's Wellness is a physician-founded practice led by Dr. Melissa Lee-Agawa, delivered in partnership with Grace & Glow MD. These articles are written by Taka Agawa, founder, with Dr. Lee-Agawa's clinical guidance throughout. Spring House, Pennsylvania. www.springhousemen.com